Overexpression of chromatin assembly factor-1 (CAF-1) p60 is predictive of adverse behaviour of prostatic cancer

Histopathology

Volumn 54, Issue 5, 2009, Pages 580-589

  Staibano, Stefania ^a,e   Mascolo, Massimo ^a   Mancini, Francesco Paolo ^b   Kisslinger, Annamaria ^a   Salvatore, Gaetano ^a   Di Benedetto, Maria ^a   Chieffi, Paolo ^c   Altieri, Vincenzo ^a   Prezioso, Domenico ^a   Ilardi, Gennaro ^a   De Rosa, Gaetano ^d   Tramontano, Donatella ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF SANNIO   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d Referral Cancer Center of Basilicata   (Italy)

^e NONE   (Italy)

Author keywords

Cell cycle; Chromatin assembly factor; Prognosis; Prostatic cancer

Indexed keywords

CHROMATIN ASSEMBLY FACTOR 1;

ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER STAGING; CONTROL GROUP; DISEASE ACTIVITY; DISEASE ASSOCIATION; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 64549163701     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2009.03266.x     Document Type: Article

References (44)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J. Clin. 2007 57 43 66.
2. Andrén O, Fall K, Franzén L, Andersson SO, Johansson JE, Rubin MA. How well does the Gleason score predict prostate cancer death? A 20-year follow-up of a population based cohort in Sweden J. Urol. 2006 175 1337 1340.
3. Kvale R, Auvinen A, Adami HO et al. Interpreting trends in prostate cancer incidence and mortality in the five nordic countries. J. Natl Cancer Inst. 2007 99 1881 1887.
4. Montironi R, Colanzi P. Predictive factors in prostate cancers. Adv. Clin. Pathol. 2001 5 19 53.
5. Thompson IM, Ankerst DP. Prostate-specific antigen in the early detection of prostate cancer. Can. Med. Assoc. J. 2007 176 1854 1858.
6. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 2001 1 34 45.
7. Furuya Y, Akakura K, Akimoto S, Inomiya H, Ito H. Pattern of progression and survival in hormonally treated metastatic prostate cancer. Int. J. Urol. 1999 6 240 244.
8. Ashida S, Nakagawa H, Katagiri T et al. Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: genome-wide gene-expression profiles of prostate cancers and PINs. Cancer Res. 2004 64 5963 5972.
9. Izawa JI, Lega I, Downey D, Chin JL, Luke PP. Do all patients with high grade prostatic intraepithelial neoplasia on initial prostatic biopsy eventually progress to clinical prostate cancer? BJU Int. 2005 96 320 323.
10. Li LC, Carroll LP, Dahiya R. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J. Natl Cancer Inst. 2005 97 103 115.
11. Schultz WA, Hatina J. Epigenetics of prostate cancer: beyond DNA methylation. J. Cell Mol. Med. 2006 10 100 125.
12. Li CL, Dahiya R. Epigenetics of prostate cancer. Front. Biosci. 2007 12 3377 3397.
13. Kornberg RD. Structure of chromatin. Annu. Rev. Biochem. 1977 46 931 954.
14. Kaufman PD, Almouzni G. DNA replication, nucleotide excision repair, and nucleosome assembly. In Elgin S, Workman J eds. Frontiers in molecular biology: chromatin structure and gene expression. Oxford, UK : Oxford University Press, 2000 24 48.
15. Mello JA, Almouzni G. The ins and outs of nucleosome assembly. Curr. Opin. Genet. Dev. 2001 11 136 141.
16. Philpott A, Krude T, Laskey RA. Nuclear chaperones. Cell. Dev. Biol. 2000 11 7 14.
17. Loyola A, Almouzni G. Histone chaperones, a supporting role in the limelight. Biochim. Biophys. Acta 2004 1677 3 11.
18. Moggs JG, Grandi P, Quivy JP et al. A CAF-1-PCNA-mediated chromatin assembly pathway triggered by sensing DNA damage. Mol. Cell. Biol. 2000 20 1206 1218.
19. Marheineke K. Nucleosome assembly activity and intracellular localization of human CAF-1 change during the cell division cycle. J. Biol. Chem. 1998 273 15279 15286.
20. Green CM, Almouzni G. Local action of the CAF-1 at sites of nucleotide excision repair in vivo. EMBO J. 2003 22 5163 5174.
21. Smith S, Stillman B. Purification and characterization of CAF-1, a human cell factor required for chromatin assembly during DNA replication in vitro. Cell 1989 58 15 25.
22. Kaufman PD, Kobayashi R, Kessler N, Stillman B. The p150 and p60 subunits of chromatin assembly factor 1 - a molecular link between newly synthesized histones and DNA replication. Cell 1995 81 1105 1114.
23. Verreault A, Kaufman PD, Kobayashi R, Stillman B. Nucleosome assembly by a complex of CAF-1 and acetylated histones H3/H4. Cell 1996 87 95 104.
24. Ridgway P, Almouzni G. CAF-1 and the inheritance of chromatin states: at the crossroads of DNA replication and repair. J. Cell Sci. 2000 113 2647 2658.
25. Ye X, Franco AA, Santos H, Nelson DM, Kaufman PD, Adams PD. Defective S phase chromatin assembly causes DNA damage, activation of the S phase checkpoint, and S phase arrest. Mol. Cell 2003 11 341 351.
26. Polo SE, Yheocharis SE, Klijaieko J, Savignoni A, Asselain B, Almouzni G. CAF-1, a marker of clinical value to distinguish quiescent from proliferative cells. Cancer Res. 2004 64 2371 2381.
27. Staibano S, Mignogna C, Lo Muzio L et al. Chromatin assembly factor-1(CAF-1) mediated regulation of cell proliferation and DNA repair: a link with the biological behaviour of squamous cell carcinoma of the tongue. Histopathology 2007 50 911 919.
28. Gleason DF, Mellinger GT. The veterans Administration Cooperative Urologic Research Group: prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J. Urol. 1974 111 58 64.
29. Gleason DF. The veterans Administration Cooperative Urologic Research Group: histological grading and clinical staging of prostatic carcinoma. In Tannenbaum M ed. Urologic pathology, the prostatic. Philadelphia : Lea & Febiger, 1977 171 197.
30. Humphrey PA, Frazier HA, Vollmer RT, Paulson DF. Stratification of pathologic features radical prostatectomy specimens that are predictive of elevated initial post-operative serum prostatic-specific antigen levels. Cancer 1993 71 1821 1827.
31. Hsu SM, Raine L, Fanger H. Use of Avidin-Biotin-Peroxidase Complex (ABC) immunoperoxidase techniques: a comparison between ABC and unlabelled antibody (PAP) procedures. J. Histochem. Cytochem. 1981 29 577 580.
32. Stanzione R, Picascia A, Chieffi P et al. Variations of proline-rich kinase, Pyk2, expression correlate with prostate cancer progression. Lab. Invest. 2001 81 51 59.
33. Kaingn ME, Narayan KS, Ohnuki Y, Lechner J, Jones LW. Establishment and characterization of a human prostatic cancer cell lines (PC3). Invest. Urol. 1979 17 16 23.
34. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of human prostate carcinoma cell line (DU145). Int. J. Cancer 1987 21 274 281.
35. Horoszewicz JS, Leong SS, Kawinski E et al. LNCaP model of human prostatic carcinoma. Cancer Res. 1983 43 1809 1818.
36. Merheineke K, Krude T. Nucleosome assembly activity and intracellular localization of human CAF-1 change during the cell division cycle. J. Biol. Chem. 1998 24 15279 15286.
37. Henikoff S. Versatile assembler. Nature 2003 423 814 817.
38. Tagami H, Ray-Gallet D, Almouzni G, Nakatami Y. H3.1 and H3.3 complexes mediate nucleosome assembly pathways dependent or independent of DNA synthesis. Cell 2004 116 51 61.
39. Shibahara K, Stillman B. Replication-dependent marking of DNA by PCNA facilitates CAF-1 coupled inheritance of chromatin. Cell 1999 96 575 585.
40. Krawitz DC, Kama T, Kaufman PD. Chromatin assembly factor I mutants defective for PCNA binding require Asf1/Hir proteins for silencing. Mol. Cell. Biol. 2002 22 614 625.
41. Taddei A, Roche D, Sibarita JB, Turner BM, Almouzni G. Duplication and maintenance of heterochromatin domains. J. Cell Biol. 1999 147 1153 1166.
42. Martini E, Roche DM, Maherineke K, Verreault A, Almouzni G. Recruitment of phosphorylated chromatin assembly factor 1 after UV irradiation of human cells. J. Cell Biol. 1998 143 563 575.
43. Seligson DB, Horvath S, Shi T et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005 30 1262 1266.
44. Kurdistani SK. Histone modifications as markers of cancer prognosis: a cellular view. Br. J. Cancer 2007 97 1 5.